BTMD biote Corp.
Q3 2025 10-Q
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Medicinal Chemicals & Botanical ProductsSEC EDGAR biote Corp. (BTMD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Management Discussion & Analysis
- • No quarterly revenue or YoY change data disclosed in MD&A
- • No profitability or margin figures reported for the quarter or YoY comparisons
Risk Factors
- • New risk: Share repurchase program authorized up to $20.0M, with $11.0M remaining as of Sept 30, 2025, introducing potential stock price volatility
- • Material update: Rising tariffs on estradiol from China and trocars from Pakistan increasing raw material costs and supply chain risks
Quarterly Financial SummaryXBRL
Revenue
$48M
Net Income
$8M
Operating Margin
17.2%
Net Margin
17.1%
ROE
-11.3%
Total Assets
$111M
Source: XBRL data from biote Corp. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on biote Corp.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.